Re Provexis Admission to AIM

Angle PLC 24 June 2005 FOR IMMEDIATE RELEASE 24 June 2005 ANGLE plc ('ANGLE' or the 'Company') First day of Dealings for venture company Provexis plc on AIM ANGLE plc, the venture management and consulting company specialising in the commercialisation of technology, is pleased to announce that its venture company Provexis plc, the nutraceutical company which develops scientifically-proven, proprietary, functional foods, supplements and medical foods, announces commencement of trading today in its ordinary shares on AIM under the ticker symbol: PSX.L. At the placing price of 5.6p per ordinary share, Provexis raised £5.9 million of equity through an institutional placing of £3.8 million (before expenses) and the conversion of £2.1 million of loans. On Admission and at the issue price the market capitalisation was approximately £14 million. Following the Placing ANGLE owns 24.8% of Provexis plc. For further details please contact: ANGLE plc Andrew Newland, Chief Executive Tel: +44 (0)1483 295830 Dawson Buck, Deputy Chief Executive Buchanan Communications Richard Darby Tel: +44 (0)20 7466 5000 Suzanne Brocks James Strong Note to editors: ANGLE plc Founded in 1994, ANGLE is an international venture management and consulting company focusing on the commercialisation of technology and the development of technology-based industry. ANGLE creates, develops and advises technology businesses on its own behalf and for its clients. ANGLE is listed on AIM (AGL.L); further information can be found on www.ANGLEplc.com Provexis plc Provexis is a nutraceutical business founded in 2000 as a joint venture with the Rowett Institute, a leading human nutrition research centre and ANGLE, and is 1 of the 8 venture companies developed under ANGLE's Progeny(R) programme to date. This information is provided by RNS The company news service from the London Stock Exchange